8-K: Fortress Biotech Announces Record Revenue and Regulatory Progress in 2023

Fortress Biotech reported record consolidated net revenue of $84.5 million for 2023 and highlighted progress on multiple regulatory fronts, including an accepted NDA for DFD-29.

Summary

• Fortress Biotech announced its financial results for the full year ended December 31, 2023, reporting record consolidated net revenue of $84.5 million.
• The majority of the revenue came from sales and milestone payments from their dermatology and rare disease businesses.
• The company's net loss attributable to common stockholders was $(68.7) million, or $(8.47) per share, for the full year 2023.
• Fortress had $83.4 million in cash, cash equivalents, and restricted cash as of December 31, 2023.
• The FDA accepted the New Drug Application (NDA) for DFD-29, with a PDUFA goal date of November 4, 2024.
• Fortress anticipates up to four regulatory decisions on NDAs and BLAs in the next 18 months.
• The company completed the asset transfer of CUTX-101 to Sentynl and expects the NDA submission to be completed in 2024.
• Journey Medical, a partner company, generated $79.2 million in total net revenue for 2023, with $59.7 million from product sales.
• Fortress raised approximately $34.9 million in gross proceeds through registered direct offerings and a public offering in 2023 and early 2024.
• A 1-for-15 reverse stock split was completed in October 2023 to comply with Nasdaq's minimum bid price requirement.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive revenue growth and regulatory progress offset by significant losses, a decrease in cash, and a CRL for cosibelimab. The sentiment is neutral to slightly negative due to the financial losses and delays.

Positives

• Fortress achieved record consolidated net revenue of $84.5 million in 2023, indicating strong sales performance.
• The FDA acceptance of the NDA for DFD-29 and the upcoming PDUFA date are positive steps towards potential market approval.
• The potential for up to four regulatory approvals in the next 18 months suggests a strong pipeline and future growth potential.
• Journey Medical's revenue growth and licensing agreement with Maruho demonstrate successful partnerships and commercialization efforts.
• The completion of the CUTX-101 asset transfer and the ongoing NDA submission indicate progress in the development pipeline.
• The company's cash position of $83.4 million provides financial stability for ongoing operations and development.
• The reduction in research and development expenses from $134.9 million in 2022 to $106.1 million in 2023 indicates improved cost management.
• The reduction in selling, general and administrative costs from $113.7 million in 2022 to $94.1 million in 2023 indicates improved cost management.
• The net loss per share improved from $(15.97) in 2022 to $(8.47) in 2023.

Negatives

• The company reported a consolidated net loss attributable to common stockholders of $(68.7) million for 2023.
• Fortress's cash position decreased by $97.6 million for the full year, from $181.0 million at the end of 2022 to $83.4 million at the end of 2023.
• Journey Medical's product net revenues decreased from $71.0 million in 2022 to $59.7 million in 2023.
• The FDA issued a complete response letter (CRL) for the cosibelimab BLA, requiring a resubmission to address manufacturing issues.
• The company had a significant accumulated deficit of $(694.870) million as of December 31, 2023.

Risks

• The company's growth strategy relies on successful acquisitions and integration of product candidates, which carries inherent risks.
• Fortress requires substantial additional funding, and there are uncertainties related to future financings.
• The company faces risks related to the early stage of many of its products under development.
• There are uncertainties related to preclinical and clinical testing, which could impact the success of product development.
• The company's ability to obtain regulatory approval for products under development is not guaranteed.
• The company faces risks related to commercializing products, securing third-party manufacturing, and managing competition.
• The company is subject to government regulation and faces risks related to patent and intellectual property matters.
• The complete response letter for cosibelimab indicates potential manufacturing issues that need to be resolved for approval.

Future Outlook

Fortress anticipates up to four regulatory decisions on NDAs and BLAs in the next 18 months and continues to advance its 25 development stage programs in 2024.

Management Comments

• Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer, said, 'In 2023, we built a significant amount of momentum to position our Company to achieve multiple milestones in 2024.'
• Dr. Rosenwald continued, 'We also generated record consolidated net revenues of $84.5 million in 2023, the majority of which came from the sales and milestone payments from our dermatology and rare disease businesses.'
• Dr. Rosenwald also stated, 'We are pleased that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) filing for DFD-29 earlier this month and look forward to the Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024.'

Industry Context

The announcement reflects the ongoing challenges and opportunities in the biopharmaceutical industry, including the need for successful clinical trials, regulatory approvals, and commercialization strategies. The focus on dermatology and rare diseases aligns with current trends in the sector, where there is a high demand for innovative treatments.

Comparison to Industry Standards

• Fortress Biotech's revenue growth of 11.6% year-over-year is a positive sign, but the company's net loss of $68.7 million is a concern.
• Compared to other biopharmaceutical companies of similar size, Fortress's R&D spending of $106.1 million is significant, indicating a commitment to innovation.
• The FDA's acceptance of the DFD-29 NDA is a positive milestone, similar to other companies achieving regulatory progress in their respective pipelines.
• The complete response letter for cosibelimab is a setback, highlighting the challenges in manufacturing and regulatory compliance faced by many biopharma companies.
• Journey Medical's revenue of $79.2 million is a positive contribution to Fortress's overall performance, but the decrease in product revenue from $71.0 million to $59.7 million is a concern.
• Companies like Amgen and Regeneron, which are larger and more established, have significantly higher revenues and profits, but Fortress is still in a growth phase.
• The reverse stock split is a common strategy for companies to maintain Nasdaq listing compliance, similar to actions taken by other companies facing similar challenges.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the decrease in cash, but encouraged by the revenue growth and regulatory progress.
• Employees may be impacted by the company's financial performance and the need for cost management.
• Customers may benefit from the potential approval of new treatments, such as DFD-29.
• Suppliers and creditors may be impacted by the company's financial health and ability to meet its obligations.

Next Steps

• Fortress will resubmit the BLA for cosibelimab to address the issues raised in the complete response letter.
• Sentynl is expected to complete the NDA submission for CUTX-101 in 2024.
• Fortress will continue to advance its 25 development stage programs.
• The company will await the FDA's decision on the DFD-29 NDA, with a PDUFA goal date of November 4, 2024.

Key Dates

Keywords

biopharmaceutical, regulatory approvals, NDA, BLA, DFD-29, cosibelimab, CUTX-101, revenue, financial results, dermatology, rare disease, Journey Medical, reverse stock split